Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes.
Authors:
Open Access
- 1 May 1986
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 136 (9) , 3390-3395
Abstract
Decay-accelerating factor (DAF) is a membrane glycoprotein found on various cells that are in contact with complement. It inhibits the formation of the C3 convertases of the complement system, both the classic (C4b2a) and alternative (C3bBb) pathways. In this investigation, we used a homobifunctional cross-linking reagent to search for a DAF ligand on the surface of cells subjected to complement attack. We found that DAF forms complexes with C4b and C3b deposited on the same erythrocytes, but not with the physiologic degradation products of these complement fragments, that is, C4d or C3dg. Taken together with prior observations that DAF action is reversible, and DAF does not affect the structure of C4b or C3b, these findings suggest that DAF functions by competitively inhibiting the uptake of C2 or factor B, and preventing the assembly of the C3 convertases.Keywords
This publication has 18 references indexed in Scilit:
- Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.Proceedings of the National Academy of Sciences, 1983
- Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.Proceedings of the National Academy of Sciences, 1983
- Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.The Journal of Immunology, 1982
- Purification of human C3b inactivator by monoclonal-antibody affinity chromatographyBiochemical Journal, 1982
- Complement receptor is an inhibitor of the complement cascade.Journal of Experimental Medicine, 1981
- Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.Journal of Experimental Medicine, 1980
- Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membraneProceedings of the National Academy of Sciences, 1979
- Complement C3 convertase: Cell surface restriction of β1H control and generation of restriction on neuraminidase-treated cellsProceedings of the National Academy of Sciences, 1978
- Activation of the alternative complement pathway due to resistance of zymosan-bound.Proceedings of the National Academy of Sciences, 1977
- ENHANCEMENT OF THE HEMOLYTIC ACTIVITY OF THE SECOND COMPONENT OF HUMAN COMPLEMENT BY OXIDATIONJournal of Experimental Medicine, 1967